US 12,006,359 B2
Methods for altering body composition by administering anti-pro/latent myostatin antibodies
Adriana Donovan, West Roxbury, MA (US); Michelle Straub, Yarmouth, ME (US); and Stefan Wawersik, Westborough, MA (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Filed by Scholar Rock, Inc., Cambridge, MA (US)
Filed on Oct. 29, 2020, as Appl. No. 17/083,917.
Application 17/083,917 is a continuation of application No. 16/360,142, filed on Mar. 21, 2019, granted, now 10,882,904.
Application 16/360,142 is a continuation of application No. 15/400,825, filed on Jan. 6, 2017, granted, now 10,287,345, issued on May 14, 2019.
Application 15/400,825 is a continuation of application No. PCT/US2016/052014, filed on Sep. 15, 2016.
Claims priority of provisional application 62/413,278, filed on Oct. 26, 2016.
Claims priority of provisional application 62/333,810, filed on May 9, 2016.
Claims priority of provisional application 62/333,816, filed on May 9, 2016.
Claims priority of provisional application 62/328,597, filed on Apr. 27, 2016.
Claims priority of provisional application 62/276,698, filed on Jan. 8, 2016.
Prior Publication US 2021/0332117 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 21/00 (2006.01); A61P 21/04 (2006.01); A61P 21/06 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/475 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 21/00 (2018.01); A61P 21/04 (2018.01); A61P 21/06 (2018.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 14/475 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 8 Claims
 
1. A method for improving body composition in a subject in need thereof, the method comprising administering to the subject a pro/latent myostatin inhibitor in an amount effective to alter body composition, wherein the pro/latent myostatin inhibitor is an antibody or antigen-binding fragment thereof comprising:
(a) a heavy chain amino acid sequence that is at least 95% identical to SEQ ID NO: 50 and a light chain amino acid sequence that is at least 95% identical to SEQ ID NO: 51;
(b) a heavy chain variable region sequence that is at least 95% identical to SEQ ID NO: 73 and a light chain variable region sequence that is at least 95% identical to SEQ ID NO: 74; or
(c) a heavy chain variable region sequence that is at least 95% identical to SEQ ID NO: 78 and a light chain variable region sequence that is at least 95% identical to SEQ ID NO: 79.